CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Zeljko Todorovic; Dusan Todorovic; Vladimir Markovic; Nevena Ladjevac; Natasa Zdravkovic; Predrag Djurdjevic; Nebojsa Arsenijevic; Marija Milovanovic; Aleksandar Arsenijevic; Jelena Milovanovic

doi:10.3390/curroncol29050293

CAR T Cell Therapy for Chronic Lymphocytic Leukemia: Successes and Shortcomings

Curr Oncol. 2022 May 18;29(5):3647-3657. doi: 10.3390/curroncol29050293.

Affiliations

¹ Department of Internal Medicine, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
² Department of Ophthalmology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
³ Center for Molecular Medicine and Stem Cell Research, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
⁴ Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.

Abstract

Chimeric antigen receptor T (CAR T) cell therapy achieved remarkable success in B-cell leukemia and lymphoma which led to its incorporation in treatment protocols for these diseases. CAR T cell therapy for chronic lymphocytic leukemia (CLL) patients showed less success compared to other malignant tumors. In this review, we discuss the published results regarding CAR T cell therapy of CLL, possible mechanisms of failures and expected developments.

Keywords: CAR NK cells; CAR T cells; CLL.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immunotherapy, Adoptive / methods
Leukemia, Lymphocytic, Chronic, B-Cell* / therapy
Lymphoma*
T-Lymphocytes

Grants and funding

This work was funded by grants from the Ministry of Education, Science and Technological Development of the Republic of Serbia (grant no. ON175069), the Serbian bilateral project with PR China (06/2018), and The Faculty of Medical Sciences, University of Kragujevac (JP 17/19).